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Oral squamous cell carcinoma (OSCC) is a heterogeneous cancer and the most prevalent type of cancer in the oral cavity [1](#eos12352-bib-0001){ref-type="ref"}, [2](#eos12352-bib-0002){ref-type="ref"}. It can spread via vascular, lymphatic [3](#eos12352-bib-0003){ref-type="ref"}, or perineural invasion [4](#eos12352-bib-0004){ref-type="ref"} to regional cervical nodes of the neck, and to the lungs, liver, or bones [5](#eos12352-bib-0005){ref-type="ref"}, [6](#eos12352-bib-0006){ref-type="ref"}. Oral carcinogenesis begins with an accumulation of genetic and epigenetic alterations in keratinocytes of the basal layer of the oral epithelium. These alterations affect normal growth, differentiation, and apoptosis of keratinocytes and can, in time, lead to transformation of normal keratinocytes into precancerous cells and to the development of precancerous lesions. These lesions clinically appear as leukoplakia or erythroplakia but histologically appear as benign hyperkeratosis, dysplasia, or carcinoma in situ. Further genetic alterations lead to transformation of the precancerous cells into cancer cells, which degrade the basement membrane and invade the underlying connective tissue, forming OSCC [7](#eos12352-bib-0007){ref-type="ref"}, [8](#eos12352-bib-0008){ref-type="ref"}, [9](#eos12352-bib-0009){ref-type="ref"}.

WNT5A is a secreted signaling protein that belongs to the WNT family of cysteine‐rich proteins. It appears to be important in the development of organs and to regulate cellular functions, including proliferation, differentiation, apoptosis, survival, polarity, migration, and invasion [10](#eos12352-bib-0010){ref-type="ref"}. WNT5A mainly activates the non‐canonical WNT/Ca^2+^ and WNT/planner cell polarity signaling pathways. It can also either inhibit or activate the canonical WNT/*β*‐catenin pathway, and the nature of this effect depends on the receptor and cellular context [11](#eos12352-bib-0011){ref-type="ref"}, [12](#eos12352-bib-0012){ref-type="ref"}, [13](#eos12352-bib-0013){ref-type="ref"}. WNT5A has been reported to increase the migration and invasion of pancreatic cancer cells by activating the canonical WNT/*β*‐catenin pathway and reducing expression of E‐cadherin [14](#eos12352-bib-0014){ref-type="ref"}. In malignant melanoma cells, WNT5A increases cell migration by down‐regulating E‐cadherin without affecting the canonical WNT/*β*‐catenin signaling [15](#eos12352-bib-0015){ref-type="ref"}. In breast cancer, on the other hand, WNT5A increases membranous expression of E‐cadherin and *β*‐catenin, increases cell adhesion, and consequently decreases cell motility [16](#eos12352-bib-0016){ref-type="ref"}.

*β*‐catenin is involved in cell adhesion but also in cell signaling as a part of the canonical WNT signaling pathway. When associated with E‐cadherin, *β*‐catenin localizes to the cell membrane and the complex contributes to the establishment of the epithelial structure and to cell--cell adhesion. Loss of E‐cadherin or the presence of canonical WNT signaling promotes accumulation of *β*‐catenin in the cytoplasm and translocation into the nucleus, where it can induce transcription of genes affecting cell proliferation, migration, and invasion [17](#eos12352-bib-0017){ref-type="ref"}, [18](#eos12352-bib-0018){ref-type="ref"}. Decreased expression of membranous *β*‐catenin and increased expression of cytoplasmic *β*‐catenin has been associated with progression of OSCC [19](#eos12352-bib-0019){ref-type="ref"}, [20](#eos12352-bib-0020){ref-type="ref"}.

E‐cadherin is a Ca^2+^‐dependent transmembrane glycoprotein that is involved in cell--cell adhesion and rearrangement of epithelial cells. The expression of E‐cadherin is regulated by different signaling pathways [21](#eos12352-bib-0021){ref-type="ref"}. Down‐regulation of E‐cadherin expression has a key role in the epithelial--mesenchymal transition (EMT) and leads to decreased cell adhesion, increased cell migration, and invasion [22](#eos12352-bib-0022){ref-type="ref"}. Decreased expression of E‐cadherin has been reported to correlate with increased invasiveness and poor prognosis in OSCC [23](#eos12352-bib-0023){ref-type="ref"}, [24](#eos12352-bib-0024){ref-type="ref"}.

So far, the expression of WNT5A protein has not been thoroughly examined in human OSCC samples by immunohistochemistry (IHC). To our knowledge, there are three published studies on the expression of WNT5A in OSCC. Two of these were in fresh‐frozen human OSCC tissues and employed quantitative PCR (qPCR) and immunoblotting to determine the levels of *WNT5A* mRNA [25](#eos12352-bib-0025){ref-type="ref"} and WNT5A protein [26](#eos12352-bib-0026){ref-type="ref"}, respectively. The single study that analyzed WNT5A protein by IHC was performed on tissue samples of rat tongue squamous cell carcinoma (SCC) [27](#eos12352-bib-0027){ref-type="ref"}. In the present study, we aimed to examine the expression of WNT5A, by IHC, in human formalin‐fixed paraffin‐embedded tissues exhibiting regions of oral mucosa with a normal appearance adjacent to the affected tissue, dysplasia, and OSCC. Because OSCC cells usually migrate collectively, thus keeping the cell‐cell junctions intact [28](#eos12352-bib-0028){ref-type="ref"}, and WNT5A increases the collective migration of OSCC cells [29](#eos12352-bib-0029){ref-type="ref"}, we also aimed to investigate if WNT5A affects expression of the cell‐adhesion proteins E‐cadherin and *β*‐catenin.

Material and methods {#eos12352-sec-0002}
====================

Tissue samples {#eos12352-sec-0003}
--------------

The experimental design of this study was approved by The Ethics Committee of the Swedish Southern Health Care Region. We reviewed anonymous diagnostic incision biopsies, from all biopsies histologically diagnosed as OSCC, at the Department of Oral Pathology, Faculty of Odontology, Malmö University, Malmö, Sweden, from 2003 to 2010. Of the 207 diagnostic incision biopsies reviewed, only 21 were included in this study according to the following criteria: the presence, in the same tissue sample, of oral mucosa of normal appearance adjacent to the affected tissue, dysplasia, and OSCC; no previous history of cancer; technically sufficient tissue material; and availability of TNM data for the primary tumor from the Swedish Cancer Register. The biopsies were extracted from different locations of the mouth: tongue (*n* = 10); buccal mucosa (*n* = 4); trigonum retromolare (*n* = 1); alveolar ridge (*n* = 5); and the floor of the mouth (*n* = 1) (Table [1](#eos12352-tbl-0001){ref-type="table-wrap"}).

###### 

Clinicopathological features of 21 patients

  Patient no.   Gender   Age (yr)   Anatomical site        Grade of dysplasia   TNM stage   OSCC differentiation
  ------------- -------- ---------- ---------------------- -------------------- ----------- ----------------------
  1             M        73         Tongue                 Severe               T2N0Mx      Well
  2             F        76         Tongue                 Severe               T1N0M0      Well
  3             F        64         Tongue                 Moderate             T1N0M0      Well
  4             F        26         Tongue                 Severe               T2N0M0      Well
  5             F        77         Alveolar ridge         Moderate             T4N0M0      Well
  6             M        59         Buccal mucosa          Moderate             TxNxMx      Well
  7             F        71         Alveolar ridge         Severe               T1N0M0      Well
  8             F        34         Tongue                 Severe               T1N0M0      Well
  9             F        66         Tongue                 Severe               TisN0M0     Well
  10            F        65         Trigonum retromolare   Mild                 T1N0M0      Well
  11            M        70         Tongue                 Mild                 T1N0M0      Well
  12            M        71         Alveolar ridge         Moderate             T2N0M0      Well
  13            M        55         Tongue                 Severe               T1N0M0      Well
  14            F        54         Buccal mucosa          Moderate             T1N0M0      Well
  15            M        65         Buccal mucosa          Moderate             T2N0M0      Moderate
  16            M        69         Tongue                 Mild                 T2N0M0      Poor
  17            F        72         Buccal mucosa          Mild                 T4aN0M0     Poor
  18            M        77         Alveolar ridge         Severe               T1N0M0      Well
  19            M        69         Floor of the mouth     Mild                 T1N0M0      Moderate
  20            F        79         Alveolar ridge         Moderate             T2N0M0      Well
  21            F        68         Tongue                 Moderate             T1N0M0      Well

F, female; M, male; OSCC, oral squamous cell carcinoma.
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Antibodies {#eos12352-sec-0004}
----------

Antibodies used for IHC were: monoclonal mouse WNT5A clone 3A4 (H00007474‐M04) from Abnova (Taipei, Taiwan); monoclonal mouse *β*‐catenin (610154) from BD Biosciences (San Jose, CA, USA); and monoclonal rabbit E‐cadherin clone 24E10 (\#3195) from Cell Signaling Technology (Danvers, MA, USA). Antibodies used for western blot analysis were: monoclonal mouse E‐cadherin (610181) and monoclonal mouse *β*‐catenin (610154) from BD Biosciences; monoclonal rabbit non‐phospho (active) *β*‐catenin (Ser33/37/Thr41) clone D13A1 (\#8814) from Cell Signaling Technology; and monoclonal mouse *α*‐tubulin clone DM1A (sc‐32293) from Santa Cruz (Dallas, TX, USA). Goat anti‐rabbit/horseradish peroxidase (HRP) (P0448) and goat anti‐mouse/HRP (P0447) were purchased from DAKO (Glostrup, Denmark).

Immunohistochemistry {#eos12352-sec-0005}
--------------------

Immunohistochemistry was performed on 3‐*μ*m‐thick serial sections of formalin‐fixed paraffin‐embedded tissues. Tissue sections were deparaffinized and rehydrated prior to heat‐induced antigen retrieval in 10 mM citrate buffer, pH 6.0, at 95°C for 20 min (for *β*‐catenin and E‐cadherin) or 40 min (for WNT5A) in a Decloaking Chamber (NxGen; Biocare Medical, Concord, CA, USA). After cooling and washing the sections with TRIS‐buffered saline containing 0.1% Tween 20 (TBS‐T, pH 7.6), non‐specific background staining was blocked with background sniper (BS966L10; Biocare Medical) for 10 min at room temperature. The sections were then incubated overnight at 4°C with the primary antibodies diluted in antibody diluent containing background reducing components (S3022; DAKO). The optimal antibody dilutions were obtained by serial dilution experiments and were as follows: WNT5A, 1:75 dilution; *β*‐catenin, 1:1,000 dilution; and E‐cadherin, 1:400 dilution. Next, endogenous peroxidase was blocked for 10 min with peroxidase blocking reagent (HPBK; S2023; DAKO) before addition of secondary antibody (goat anti‐mouse/rabbit/HRP; ENVISION System, K5007; DAKO) for 20 min at room temperature. The immunoreaction was then visualized with diaminobenzidine (DAB; K5007; DAKO). The tissue sections were counterstained with hematoxylin, then dehydrated and mounted. After each step, the slides were washed with TBS‐T. N‐Universal negative‐control mouse (N1698; DAKO), N‐Universal negative‐control rabbit (N1699; DAKO), and omission of primary antibody were the negative controls. Placenta, normal breast tissue, and breast cancer tissue were the positive controls.

Evaluation of IHC {#eos12352-sec-0006}
-----------------

Expression of WNT5A, *β*‐catenin, and E‐cadherin protein was evaluated semiquantitatively by two of the authors (Z.P. and P.L.). Each author assessed expression of these proteins in serial tissue sections of oral mucosa with a normal appearance, dysplasia, and OSCC using a Nikon Eclipse 80i light microscope (Nikon, Tokyo, Japan), with 40 ×  objective, in at least two visual fields in two to four cell layers of normal appearing oral mucosa and of dysplasia, and in the periphery of OSCC islands located at the invasive front. The periphery was considered as the first or second cancer‐cell layer closest to the connective tissue. The tissues were graded as positive if ≥50% of cells showed immunoreactivity for a protein, and negative if \<50% of cells showed immunoreactivity for this protein [24](#eos12352-bib-0024){ref-type="ref"}, [30](#eos12352-bib-0030){ref-type="ref"}. Furthermore, the intensity of the positive immunoreaction was graded as weak or strong and was assessed in cytoplasm for WNT5A; in membrane, cytoplasm for *β*‐catenin; and in membrane for E‐cadherin.

Cell culture and treatment {#eos12352-sec-0007}
--------------------------

Two human tongue SCC cell lines -- SCC9 (CRL‐1629, lot 4372272) and SCC25 (CRL‐1628, lot 58075871) -- were acquired from ATCC (Manassas, VA, USA) and maintained as previously described [29](#eos12352-bib-0029){ref-type="ref"}. All incubations were at 37°C and 5% CO~2~. The cells were cultured in six‐well plates until 80% confluence was reached, rinsed with PBS, incubated with serum‐free medium overnight, rinsed again with PBS, and treated either with 0.1% BSA in PBS as the control or with 0.4 *μ*g/ml of recombinant WNT5A (rWNT5A; 645‐WN; R&D Systems, Minneapolis, MN, USA) in serum‐free medium. After 48 h of treatment, expression of protein in the cells was analyzed using western blotting.

Western blot analysis {#eos12352-sec-0008}
---------------------

Western blot analysis was carried out as previously described [29](#eos12352-bib-0029){ref-type="ref"}. In brief, cells were lysed, and 30 *μ*g of protein was loaded onto an 8% sodium dodecyl sulfate polyacrylamide electrophoresis gel (SDS‐PAGE). Following semi‐dry blotting, the membranes were either incubated with 3% (w/v) non‐fat skimmed milk powder (06‐019; Scharlab, Barcelona, Spain) in TBS‐T for 30 min before addition of primary antibodies against E‐cadherin (1:1,000 dilution) and *α*‐tubulin (1:10,000 dilution), or incubated with 3% (w/v) BSA in TBS‐T for 30 min before addition of the primary antibodies against non‐phosphorylated (active) *β*‐catenin (1:1,000 dilution) and total *β*‐catenin (1:2,000 dilution). After incubation with secondary antibodies, the immunoreaction was developed with a Chemiluminescence HRP substrate (Millipore, Temecula, CA, USA).

Statistical analysis {#eos12352-sec-0009}
--------------------

The immunohistochemical data were statistically analyzed using SPSS Statistics 23.0 software (IBM, Armonk, NY, USA). The differences, within a single biopsy, in expression of WNT5A, *β*‐catenin, and E‐cadherin between oral mucosa with normal appearance, dysplasia, and OSCC were estimated using the two‐tailed Wilcoxon signed‐rank test. The correlation between expression of WNT5A and *β*‐catenin or E‐cadherin, as well as the correlation between expression of WNT5A protein and tumor size (T), were determined using two‐tailed Spearman rank correlations. Statistical analysis of the western blot analysis data was performed using the GraphPad Prism 5.0 software (GraphPad Software, San Diego, CA, USA). The experiments were performed at least three times and data are presented as mean ± standard error of the mean. Differences in the expression of protein between two groups were determined using the paired, two‐tailed Student\'s *t*‐test.

Results {#eos12352-sec-0010}
=======

Histopathologic findings {#eos12352-sec-0011}
------------------------

The clinicopathologic characteristics of the 21 patients in this study are presented in Table [1](#eos12352-tbl-0001){ref-type="table-wrap"}. The patient cohort, with a median age of 69 yr, consisted predominantly of female patients (57.1%) and the most common location of OSCC was in the tongue (47.6%). The grade of dysplasia differed within the group -- five (23.8%) patients had mild grade, eight (38.1%) patients had moderate grade, and eight (38.1%) patients had severe grade. According to the TNM staging that had been determined at the primary surgery, most of the OSCCs were small: T1 (11; 52.4%) and T2 (six; 28.6%). Seventeen (81%) of the 21 patients had been evaluated as having well‐differentiated OSCCs, while two (9.5%) each had moderately or poorly differentiated OSCCs.

Expression of WNT5A protein in normal appearing oral mucosa, dysplasia, and OSCC {#eos12352-sec-0012}
--------------------------------------------------------------------------------

The expression of WNT5A protein in normal appearing oral mucosa, dysplasia, and OSCC is presented in Fig. [1](#eos12352-fig-0001){ref-type="fig"}. Cytoplasmic expression of WNT5A was absent in all samples of normal appearing oral mucosa, while it was detected in eight (38.1%) of the dysplastic tissues. Of these eight samples, three were diagnosed with moderate dysplasia while five were diagnosed with severe dysplasia. There was a statistically significantly higher expression of WNT5A in dysplasia compared with normal appearing oral mucosa (*P *=* *0.005; Table [2](#eos12352-tbl-0002){ref-type="table-wrap"}). In 17 (81%) OSCCs, there was cytoplasmic WNT5A expression in the periphery of cancer islands located at the invasive front of OSCC. Among the well‐differentiated OSCCs, WNT5A was expressed in 76.5% (13/17) of samples, and all moderately and poorly differentiated OSCCs were positive for WNT5A. There was a statistically significant higher expression of WNT5A in OSCCs compared with both normal appearing oral mucosa (*P *\<* *0.001) and dysplasia (*P *=* *0.001; Table [2](#eos12352-tbl-0002){ref-type="table-wrap"}). Furthermore, no correlation was found between cytoplasmic WNT5A expression and tumor size (T) (*ρ *= −0.013; *P *=* *0.955). Nuclear WNT5A immunostaining was detected in 61.9% of normal appearing oral mucosa samples, 81% of dysplastic tissues, and 61.9% of OSCCs (data not shown).

![Expression of WNT5A in different tissue regions. (A and B) Nuclear expression of WNT5A in oral mucosa with normal appearance. (C and D) Cytoplasmic and nuclear expression of WNT5A in severe‐grade dysplasia (black arrows). (E and F) Cancer islands; black arrows indicate expression of WNT5A in the cytoplasm in the periphery of cancer islands and red arrows indicate the absence of expression of WNT5A in the central part of the cancer islands. Scale bar = 50 *μ*m.](EOS-125-237-g001){#eos12352-fig-0001}

###### 

Expression of WNT5A, *β*‐catenin, and E‐cadherin in oral mucosa with a normal appearance, dysplasia, and at the invasive front of oral squamous cell carcinoma (OSCC)

                Staining   Oral mucosa                                      Dysplasia                                        OSCC                
  ------------- ---------- ------------------------------------------------ ------------------------------------------------ ------ --- ---- --- ---
  Cytoplasmic   Negative   21                                               5                                                5      3   4    0   0
  WNT5A         Weak       0                                                0                                                3      5   8    1   1
  Strong        0          0                                                0                                                0      5   1    1   
  *P*                      \<0.001[a](#eos12352-note-0002){ref-type="fn"}   0.001[b](#eos12352-note-0003){ref-type="fn"}                         
                           0.005[c](#eos12352-note-0004){ref-type="fn"}                                                                          
  Membranous    Negative   0                                                0                                                1      1   3    0   0
  *β*‐catenin   Weak       0                                                1                                                0      2   10   2   2
  Strong        21         4                                                7                                                5      4   0    0   
  *P*                      \<0.001[a](#eos12352-note-0002){ref-type="fn"}   0.001[b](#eos12352-note-0003){ref-type="fn"}                         
                           0.038[c](#eos12352-note-0004){ref-type="fn"}                                                                          
  Cytoplasmic   Negative   21                                               3                                                4      0   8    2   0
  *β*‐catenin   Weak       0                                                2                                                4      6   8    0   1
  Strong        0          0                                                0                                                0      1   0    1   
  *P*                      0.002[a](#eos12352-note-0002){ref-type="fn"}     0.763[b](#eos12352-note-0003){ref-type="fn"}                         
                           0.001[c](#eos12352-note-0004){ref-type="fn"}                                                                          
  Membranous    Negative   0                                                0                                                0      0   5    0   2
  E‐cadherin    Weak       0                                                2                                                2      1   11   1   0
  Strong        21         3                                                6                                                7      1   1    0   
  *P*                      \<0.001[a](#eos12352-note-0002){ref-type="fn"}   \<0.001[b](#eos12352-note-0003){ref-type="fn"}                       
                           0.025[c](#eos12352-note-0004){ref-type="fn"}                                                                          

OSCC compared with oral mucosa with a normal appearance.

OSCC compared with dysplasia.

Dysplasia compared with oral mucosa with a normal appearance.
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Expression of *β*‐catenin protein in normal appearing oral mucosa, dysplasia, and OSCC {#eos12352-sec-0013}
--------------------------------------------------------------------------------------

The expression of *β*‐catenin is presented in Fig. [2](#eos12352-fig-0002){ref-type="fig"}. Its expression in all normal appearing epithelial cells was exclusively membranous, with no expression detected in the cytoplasm. Nineteen (90.5%) of the dysplastic tissues showed expression of membranous *β*‐catenin, which was distributed almost equally among the three grades of dysplasia (Table [2](#eos12352-tbl-0002){ref-type="table-wrap"}), and 12 (57.1%) of the dysplastic samples showed expression of cytoplasmic *β*‐catenin. This expression increased with grade of dysplasia: cytoplasmic expression was present in two samples with mild‐grade dysplasia, in four samples with moderate‐grade dysplasia, and in six samples with severe‐grade dysplasia. There was a statistically significantly higher expression of cytoplasmic *β*‐catenin in dysplasia compared with normal appearing oral mucosa (*P *=* *0.001) (Table [2](#eos12352-tbl-0002){ref-type="table-wrap"}). Membranous *β*‐catenin was expressed in 18 (85.7%) of OSCCs, and there was no difference with respect to differentiation grade. Cytoplasmic *β*‐catenin was expressed in 11 (52.4%) of the OSCCs, which is more than in normal appearing oral mucosa (*P *=* *0.002; Table [2](#eos12352-tbl-0002){ref-type="table-wrap"}). There was less expression of membranous *β*‐catenin in OSCC tissues than in either normal appearing oral mucosa (*P *\<* *0.001) or dysplasia (*P *=* *0.001; Table [2](#eos12352-tbl-0002){ref-type="table-wrap"}). Nuclear *β*‐catenin expression was detected in only one OSCC sample (data not shown).

![Expression of *β*‐catenin in different tissue regions. (A, B) Normal appearing oral mucosa showing membranous expression of *β*‐catenin. (C, D) Membranous and cytoplasmic expression of *β*‐catenin in severe‐grade dysplasia (black arrows). (E, F) Cancer islands: black arrows indicate expression of *β*‐catenin in the membrane in the periphery of cancer islands and red arrows indicate expression of *β*‐catenin in the central part of the cancer islands. Scale bar = 50 *μ*m.](EOS-125-237-g002){#eos12352-fig-0002}

Expression of E‐cadherin protein in normal appearing oral mucosa, dysplasia, and OSCC {#eos12352-sec-0014}
-------------------------------------------------------------------------------------

The expression of E‐cadherin protein in normal appearing oral mucosa, dysplasia, and OSCC is presented in Fig. [3](#eos12352-fig-0003){ref-type="fig"}. Based on positive immunostaining, expression of membranous E‐cadherin was present in all normal appearing oral mucosa and dysplastic tissues (Table [2](#eos12352-tbl-0002){ref-type="table-wrap"}), but in only 14 (66.7%) of OSCCs. Also, membranous E‐cadherin was not expressed in the poorly differentiated carcinomas. The difference in expression of E‐cadherin between OSCCs and the non‐cancerous regions was statistically significant: *P *\<* *0.001 for OSCCs compared with normal appearing oral mucosa, and *P *\<* *0.001 for OSCCs compared with dysplasia.

![Expression of E‐cadherin in different tissue regions. (A, B) Normal appearing oral mucosa showing membranous expression of E‐cadherin. (C, D) Membranous expression of E‐cadherin in severe‐grade dysplasia. (E, F) Expression of E‐cadherin in cancer islands: black arrows indicate the absence of membranous expression of E‐cadherin in the periphery of cancer islands and red arrows indicate the presence of membranous expression of E‐cadherin in the central part of the cancer islands. Scale bar = 50 *μ*m.](EOS-125-237-g003){#eos12352-fig-0003}

Association of WNT5A expression with *β*‐catenin and E‐cadherin in OSCC {#eos12352-sec-0015}
-----------------------------------------------------------------------

Correlation was not observed between the expression of WNT5A and cytoplasmic *β*‐catenin (*ρ *= 0.026; *P *=* *0.910), between WNT5A and membranous *β*‐catenin (*ρ *= −0.155; *P *=* *0.504), or between WNT5A and E‐cadherin (*ρ *= −0.155; *P *=* *0.502) in OSCC tissues (data not shown). Furthermore, stimulation of OSCC cells, SCC9 and SCC25, with rWNT5A for 48 h had no effect on the expression of E‐cadherin, active *β*‐catenin, or total *β*‐catenin proteins (Fig. [4](#eos12352-fig-0004){ref-type="fig"}).

![Effect of recombinant WNT5A (rWNT5A) on expression of *β*‐catenin and E‐cadherin in SCC9 and SCC25. (A, E) Representative western blots of expression of active *β*‐catenin, total *β*‐catenin, and E‐cadherin after stimulation with rWNT5A. (B, F) Quantification of relative E‐cadherin; (C, G) quantification of active *β*‐catenin; (D, H) quantification of total *β*‐catenin. All quantifications were performed on four separate experiments.](EOS-125-237-g004){#eos12352-fig-0004}

Discussion {#eos12352-sec-0016}
==========

The function of WNT5A has been extensively studied in different types of cancer [30](#eos12352-bib-0030){ref-type="ref"}, [31](#eos12352-bib-0031){ref-type="ref"}, [32](#eos12352-bib-0032){ref-type="ref"}, [33](#eos12352-bib-0033){ref-type="ref"}, and WNT5A was suggested to promote migration and invasion of OSCC cells [29](#eos12352-bib-0029){ref-type="ref"}. The expression of WNT5A protein in human OSCC tissues has, however, been less well studied [25](#eos12352-bib-0025){ref-type="ref"}, [26](#eos12352-bib-0026){ref-type="ref"}. Therefore, we aimed to analyse, by IHC, the expression of WNT5A in normal appearing oral mucosa adjacent to the affected tissue, dysplasia, and OSCC in human tissues and to examine the relationship between expression of WNT5A protein and that of *β*‐catenin and E‐cadherin.

The diagnostic incision biopsies used in this study were selected according to specific criteria: the presence of normal appearing oral mucosa adjacent to the affected tissue, dysplasia, and OSCC in the same tissue sample; no previous history of cancer; technically sufficient tissue material; and available TNM data of the primary tumor from Swedish Cancer Register. Only 21 out of the 207 diagnostic incision biopsies diagnosed as OSCC, qualified for use in this study. The OSCCs of this cohort were predominantly well differentiated and at the early stage of OSCC (T1 and T2), which provided a reliable basis for evaluation of how early in the process of the oral carcinogenesis WNT5A protein can be detected, as well as the importance of WNT5A in the progression of OSCC. The epithelium of the oral mucosa in the patient samples used in this study is actually an epithelium that might be genetically altered by the adjacent precancerous and cancerous epithelium and thus it cannot be considered as normal epithelium. We found no expression of WNT5A protein in the normal appearing mucosa, but we found a statistically significant difference between expression of WNT5A in OSCC and in normal appearing oral mucosa; between expression of WNT5A in OSCC and in dysplasia; and between expression of WNT5A in dysplasia and in normal appearing oral mucosa. It seems that expression of WNT5A gradually increased throughout the multistep process of carcinogenesis. Furthermore, we observed more WNT5A expression in the OSCC islands present in the muscle layer compared to OSCC islands in the lamina propria (data not shown). The high expression of WNT5A found in our study is supported by results of previous studies in which high levels of *WNT5A* mRNA and WNT5A protein have been reported in human oral tissue samples, as well as in rat tongue carcinoma [25](#eos12352-bib-0025){ref-type="ref"}, [26](#eos12352-bib-0026){ref-type="ref"}, [27](#eos12352-bib-0027){ref-type="ref"}. [prgomet]{.smallcaps} *et al*. showed that rWNT5A increased migration and invasion of the OSCC cell lines, SCC9 and SCC25 [29](#eos12352-bib-0029){ref-type="ref"}. Because these cell lines are obtained from early‐stage OSCCs (SCC9 T1N1 and SCC25 T1N1M0) [34](#eos12352-bib-0034){ref-type="ref"} and the present patient cohort comprised predominantly well‐differentiated and early‐stage OSCCs (T1 and T2), it seems reasonable to conclude that WNT5A has an early role in the invasiveness of OSCC. Regarding the possible mechanisms, the presence of WNT5A may up‐regulate other molecules, for example, matrix metalloproteinases [15](#eos12352-bib-0015){ref-type="ref"}, [33](#eos12352-bib-0033){ref-type="ref"}, [35](#eos12352-bib-0035){ref-type="ref"} and Laminin *γ*2 [30](#eos12352-bib-0030){ref-type="ref"}, which are involved in degradation of the basal lamina and metastatic spread of OSCC [36](#eos12352-bib-0036){ref-type="ref"}, [37](#eos12352-bib-0037){ref-type="ref"}. Thus, WNT5A may have potential as a biological marker for progression of dysplasia to OSCC and a cancer‐promoting role in OSCC. Further investigations of how WNT5A affects downstream molecules involved in metastatic spread of OSCC, as well as further analyses of WNT5A expression in larger patient cohorts, are required to confirm these speculations.

Our next step was based on the fact that WNT5A is expressed in OSCC and increases migration of OSCC cells. We chose to study the effect of WNT5A on expression of *β*‐catenin and E‐cadherin, in order to evaluate if the WNT5A‐induced migration involved alterations in cell‐adhesion proteins *β*‐catenin and E‐cadherin. In our study, expression of membranous *β*‐catenin was lower in OSCCs than in dysplasia or normal appearing oral mucosa, while expression of cytoplasmic *β*‐catenin increased with accumulative severity of dysplasia and was present in half of the OSCCs. Similar findings on decreased expression of membranous *β*‐catenin and progression of oral carcinogenesis have been reported [19](#eos12352-bib-0019){ref-type="ref"}, [38](#eos12352-bib-0038){ref-type="ref"}, [39](#eos12352-bib-0039){ref-type="ref"}. The slight decrease in expression of membranous *β*‐catenin and increase in expression of cytoplasmic *β*‐catenin that we observed in OSCCs was not a result of increased expression of WNT5A, because stimulation of OSCC cells with rWNT5A had no effect on *β*‐catenin expression. A possible explanation for this lack of effect on *β*‐catenin expression could be that WNT5A increases protein kinase C (PKC) in the same OSCC cell lines [29](#eos12352-bib-0029){ref-type="ref"}. Evidence that WNT5A increased migration of ovarian cancer cells [40](#eos12352-bib-0040){ref-type="ref"} and melanoma cells [15](#eos12352-bib-0015){ref-type="ref"} through PKC, without affecting expression of *β*‐catenin, supports our explanation. In our study, expression of nuclear *β*‐catenin was present in only one OSCC sample. However, [ishida]{.smallcaps} *et al*. found nuclear *β*‐catenin to be expressed in 67% of OSCC samples and they suggested that expression of nuclear *β*‐catenin is associated with cell invasion [41](#eos12352-bib-0041){ref-type="ref"}. The small number of samples (i.e. one) showing expression of nuclear *β*‐catenin in this study, along with the findings that WNT5A did not have any effect on *β*‐catenin expression, may indicate that *β*‐catenin is not involved in cell signaling but rather in cell adhesion in OSCC tissue. This has been previously reported by [yu]{.smallcaps} *et al*. [39](#eos12352-bib-0039){ref-type="ref"}.

E‐cadherin is involved in cell--cell adhesion and has been widely studied in OSCCs [23](#eos12352-bib-0023){ref-type="ref"}, [24](#eos12352-bib-0024){ref-type="ref"}, [42](#eos12352-bib-0042){ref-type="ref"}, [43](#eos12352-bib-0043){ref-type="ref"}, [44](#eos12352-bib-0044){ref-type="ref"}, although its association with WNT5A in OSCC is uncertain. We observed different levels of E‐cadherin expression in the three tissue regions we studied: less membranous E‐cadherin expression was seen in OSCC than in dysplasia or normal appearing oral mucosa. Other studies have reported even greater differences of membranous E‐cadherin expression at the invasive front of OSCCs, and the loss of membranous E‐cadherin expression was suggested to enhance the invasiveness of OSCC [43](#eos12352-bib-0043){ref-type="ref"}, [45](#eos12352-bib-0045){ref-type="ref"}. Although our work is in agreement with [costa]{.smallcaps} *et al*. [43](#eos12352-bib-0043){ref-type="ref"}, additional immunohistochemical experiments should be performed with a larger patient cohort to confirm this pattern. Furthermore, we evaluated the correlation of E‐cadherin and WNT5A expression based on previous studies reporting the effect of WNT5A on expression of E‐cadherin [14](#eos12352-bib-0014){ref-type="ref"}, [15](#eos12352-bib-0015){ref-type="ref"}, [16](#eos12352-bib-0016){ref-type="ref"}. We found no correlation between low membranous expression of E‐cadherin and the high expression of WNT5A. Moreover, expression of E‐cadherin in OSCC cell lines was not affected by stimulation of the cells with rWNT5A. These findings suggest that WNT5A might be involved in the invasiveness of OSCC without affecting the expression of E‐cadherin. A similar suggestion has been proposed by [ren]{.smallcaps} *et al*., who showed that WNT5A can enhance the migration and invasion of epidermoid carcinoma cells without down‐regulating E‐cadherin [46](#eos12352-bib-0046){ref-type="ref"}. Our findings, which are in accordance with [jensen]{.smallcaps} *et al*. [47](#eos12352-bib-0047){ref-type="ref"}, suggest that E‐cadherin is not always required for the migration and invasion of OSCC.

Based on our results, we conclude that WNT5A promotes progression of OSCC without affecting the canonical WNT/*β*‐catenin pathway or down‐regulation of E‐cadherin, and propose that WNT5A expression should be explored as an indicator of transformation of dysplasia to OSCC.
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